Highlights

  • Immunome shares rose over 15% after phase 3 trial results for varegacestat were announced.
  • Varegacestat reduced the risk of disease progression or death in desmoid tumors by 84%.
  • The trial met primary and key secondary endpoints, including tumor volume and pain reduction.

Immunome (NASDAQ:IMNM) jumped more than 15% on Monday after the company reported positive results from its phase 3 study of varegacestat. The investigational treatment targets patients with progressing desmoid tumors.

Understanding Desmoid Tumors
Desmoid tumors are rare and locally aggressive growths that can lead to organ damage. In the U.S., approximately 1,000 to 1,650 people are diagnosed each year. The condition can significantly affect patients physically and emotionally due to its unpredictable nature and the limitations of existing treatment options.

Phase 3 Trial Findings
The phase 3 study demonstrated that varegacestat achieved its primary endpoint by improving progression-free survival. The trial reported an 84% reduction in the risk of disease progression or death compared to placebo. Secondary endpoints, including reductions in tumor volume and pain intensity, were also met.

Share Price Snapshot
IMNM closed at USD 22.64 on 15 December 2025, up 15.69% for the day. The stock opened at USD 22.92, with a high of USD 25.30 and a low of USD 21.22.